(Q40732795)

23 September 2017

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma (English)

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

15 October 2022

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

15 October 2022

author name string

Lewis JL Jr

9

1 reference

23 September 2017

T. B. Hakes

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

E. Chalas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

W. J. Hoskins

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

W. B. Jones

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

M. Markman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

S. C. Rubin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

D. Chapman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

L. Almadrones

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

J. L. Lewis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612505

15 October 2022

language of work or name

English

0 references

publication date

1 June 1992

1 reference

full work available at URL

23 September 2017

https://api.elsevier.com/content/article/PII:0090825892903053?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

https://api.elsevier.com/content/article/PII:0090825892903053?httpAccept=text/plain

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

15 October 2022

1 reference

23 September 2017

45

1 reference

23 September 2017

284-289

1 reference

23 September 2017

3

1 reference

Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation

23 September 2017

3

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

15 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

15 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Nonparametric Estimation from Incomplete Observations

15 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

The role of maintenance therapy in disseminated testicular cancer

15 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors

15 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

15 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Duration of therapy in adjuvant chemotherapy trials

15 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study

15 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture

15 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-hodgkin's lymphoma

15 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia

15 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia

15 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukemia

15 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/0090-8258(92)90305-3

15 October 2022

Identifiers

1 reference

23 September 2017

1 reference